ESTRELLA IMMUNOPHARMA, INC. Operating Income
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Operating Income of -$2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for the quarter ending 2026-06-30 was -$2.08M.
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for the quarter ending 2026-03-31 was -$2.29M.
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for the quarter ending 2025-12-31 was -$613.20K.
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for the quarter ending 2025-09-30 was -$4.80M.
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for fiscal 2025 was -$13.06M.
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for fiscal 2024 was -$7.31M.
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for fiscal 2023 was -$11.11M.
- ESTRELLA IMMUNOPHARMA, INC. operating income (loss) for fiscal 2022 was -$1.57M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.08M 10-Q · filed 2026-08-13 | -$4.27M 10-Q · filed 2026-08-13 | -$4.99M derived: sum of 3 quarters · filed 2026-08-13 | -$9.79M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$2.29M 10-Q · filed 2026-05-18 | -$2.91M derived: sum of 2 quarters · filed 2026-05-18 | -$7.71M derived: sum of 3 quarters · filed 2026-05-18 | -$13.25M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$613.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$5.41M derived: sum of 2 quarters · filed 2026-03-18 | -$10.96M derived: sum of 3 quarters · filed 2026-08-13 | -$13.06M 10-K · filed 2026-03-18 | |
| 2025-09-30 | -$4.80M 10-Q · filed 2025-11-12 | -$10.35M derived: sum of 2 quarters · filed 2026-08-13 | -$12.45M 10-Q · filed 2025-11-12 | -$13.50M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$5.54M 10-Q · filed 2026-08-13 | -$7.65M 10-Q · filed 2026-08-13 | -$8.70M derived: sum of 3 quarters · filed 2026-08-13 | -$12.08M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$2.10M 10-Q · filed 2026-05-18 | -$3.15M derived: sum of 2 quarters · filed 2026-05-18 | -$6.53M derived: sum of 3 quarters · filed 2026-05-18 | -$10.48M derived: sum of 4 quarters · filed 2026-05-18 | |
| 2024-12-31 | -$1.05M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | -$4.43M 10-K · filed 2026-03-18 | -$8.38M derived: sum of 3 quarters · filed 2026-03-18 | -$8.85M derived: sum of 4 quarters · filed 2026-03-18 | |
| 2024-09-30 | -$3.38M 10-Q · filed 2025-11-12 | -$7.33M derived: sum of 2 quarters · filed 2025-11-12 | -$7.80M 10-Q · filed 2025-11-12 | -$8.82M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$3.95M 10-Q · filed 2025-08-12 | -$4.42M 10-Q · filed 2025-08-12 | -$5.44M derived: sum of 3 quarters · filed 2025-08-12 | -$7.31M 10-KT · filed 2025-03-25 | |
| 2024-03-31 | -$469.53K 10-Q · filed 2025-05-14 | -$1.49M derived: sum of 2 quarters · filed 2025-05-14 | -$3.36M 10-Q · filed 2024-05-15 | -$3.53M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$1.02M 10-Q · filed 2024-02-14 | -$2.89M 10-Q · filed 2024-02-14 | -$3.06M derived: sum of 3 quarters · filed 2024-11-14 | -$5.80M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-09-30 | -$1.87M 10-Q · filed 2024-11-14 | -$2.04M derived: sum of 2 quarters · filed 2024-11-14 | -$4.78M derived: sum of 3 quarters · filed 2024-11-14 | -$7.54M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$169.24K 10-Q · filed 2023-08-01 | -$318.89K 10-Q · filed 2023-08-01 | -$5.67M derived: sum of 3 quarters · filed 2024-05-15 | -$11.11M 10-K · filed 2024-09-27 | |
| 2023-03-31 | -$2.74M 10-Q · filed 2024-05-15 | -$149.65K 10-Q · filed 2023-05-18 | -$5.50M derived: sum of 2 quarters · filed 2024-05-15 | -$8.38M 10-Q · filed 2024-05-15 | -$8.81M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$2.76M 10-Q · filed 2024-02-14 | -$5.64M 10-Q · filed 2024-02-14 | -$6.07M derived: sum of 3 quarters · filed 2024-02-14 | -$1.57M 10-K · filed 2023-03-14 | |
| 2022-09-30 | -$2.89M 10-Q · filed 2023-11-20 | -$549.18K 10-Q · filed 2022-11-14 | -$3.31M derived: sum of 2 quarters · filed 2023-11-20 | -$1.12M 10-Q · filed 2022-11-14 | -$3.59M derived: sum of 4 quarters · filed 2023-11-20 |
| 2022-06-30 | -$423.76K 10-Q · filed 2023-08-01 | -$568.71K 10-Q · filed 2023-08-01 | -$705.36K derived: sum of 3 quarters · filed 2023-08-01 | -$813.47K derived: sum of 4 quarters · filed 2023-08-01 | |
| 2022-03-31 | -$144.94K 10-Q · filed 2023-05-18 | -$281.59K derived: sum of 2 quarters · filed 2023-05-18 | -$389.71K derived: sum of 3 quarters · filed 2023-05-18 | -$393.27K derived: sum of 4 quarters · filed 2023-05-18 | |
| 2021-12-31 | -$136.65K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$244.77K derived: sum of 2 quarters · filed 2023-03-14 | -$248.33K derived: sum of 3 quarters · filed 2023-03-14 | -$249.15K 10-K · filed 2023-03-14 | |
| 2021-09-30 | -$108.11K 10-Q · filed 2022-11-14 | -$111.67K derived: sum of 2 quarters · filed 2022-11-14 | -$112.49K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$3.56K 10-Q · filed 2022-08-08 | -$4.38K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$819.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |